Stock Analiz

ZBH vs SNN stock comparison

Zimmer Biomet vs. Smith & Nephew · data as of November 13, 2026

Zimmer Biomet (ZBH) has a market value of about $19.5B, Smith & Nephew (SNN) about $13.1B. Over their latest twelve months Zimmer Biomet had revenue of $8.6B and Smith & Nephew $6.3B.

On our five checks Smith & Nephew scores higher: 2.6 out of 5 (average) against 2.2 (weak).

By area, the stronger company is Smith & Nephew on value; Smith & Nephew on future growth; Zimmer Biomet on shareholder returns.

Smith & Nephew is cheaper on earnings (P/E 21.3 vs. 26.1).

Zimmer Biomet leads on 9 of the compared lines and Smith & Nephew on 12.

Side by side

ZBHSNN
Size and price
Market cap$19.5B$13.1B
Share price$103.21$31.28
Score
Overall score (of 5)2.22.6
Value13
Future growth12
Track record11
Financial health33
Shareholder returns54
Valuation
P/E (TTM)26.121.3
Forward P/E11.413.3
Price / free cash flow11.915.3
Price / sales2.32.1
EV / EBITDA11.711.3
PEG—3.07
DCF value vs. price−12%−17%
Business
Revenue$8.6B$6.3B
Net income$767M$635M
Free cash flow$1.6B$855M
Net margin9.0%10.1%
Gross margin (5-yr avg.)71.0%69.5%
ROIC (5-yr avg.)4.8%6.1%
Growth
Revenue growth (1 yr)7.2%6.1%
Revenue growth (5 yrs, per year)6.1%6.2%
EPS growth (5 yrs, per year)—6.9%
Balance sheet and payouts
Net cash (cash minus debt)-$7.1B-$2.6B
Dividend yield0.93%2.54%
Shareholder yield3.4%6.4%
Analysts
Upside to average target+13%+6%
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: ZBH TTM to September 30, 2026, SNN TTM to June 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Zimmer Biomet or Smith & Nephew?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Smith & Nephew scores 2.6 out of 5 and Zimmer Biomet 2.2; the table shows where each one is stronger.

Is Zimmer Biomet cheaper than Smith & Nephew?

On trailing earnings, Smith & Nephew trades at a P/E of 21.3 and Zimmer Biomet at 26.1, so Smith & Nephew is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Zimmer Biomet or Smith & Nephew?

Over five years Smith & Nephew grew revenue about 6.2% a year and Zimmer Biomet about 6.1% a year.

Which pays a higher dividend?

Zimmer Biomet yields 0.93% and Smith & Nephew 2.54%.

Full Zimmer Biomet analysis → Full Smith & Nephew analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.